A year after the Brexit referendum, the pharmaceutical industry is already preparing for what is likely to be one of the biggest manufacturing transformations in the industry’s history.
A major shift is taking place as the UK prepares to leave the European Union.
But before Brexit, the UK had been one of only two countries in the world to produce its own medicines.
And as a result, the country had a lot of influence in how drugs were produced.
Now, with Brexit looming, the industry is expecting a major shift.
And it may not be the same as the one that Britain experienced a decade ago.
Read more”It will be very different to what we had,” said Andrew Haldane, CEO of the Pharmaceutical Manufacturers of America, the trade group that represents the industry.
“We are going to have to adapt to new regulatory requirements and the regulatory environment.”
The change is already being seen in the pharmaceutical sector, with the industry now using its own factories in order to meet its new production quotas.
That could mean that more drugs may be produced outside the UK.
And that could have consequences for the country’s pharmaceutical industry.
“We have already seen an impact on the industry in other countries, and that will be a factor with Brexit,” Haldanes said.
The industry has already seen its share of the manufacturing pie shrink since the Brexit decision.
With the UK’s pharmaceutical manufacturing sector being a major part of the economy, it will be especially hard to compete in a world where demand is increasing.
Since the Brexit outcome, pharmaceutical companies have started to adjust.
Some have shifted production to other countries or shifted manufacturing from the UK to other parts of Europe.
Some manufacturers are shifting production to countries outside the EU.
But in all of those cases, the move has been done with the aim of lowering costs.
For pharmaceutical companies, that could mean making cheaper drugs for patients, who are often less able to afford the expensive medications.
The pharmaceutical industry may also be forced to change the way it uses its own patents to ensure that its products are safe and effective.
But for now, it’s still very much a manufacturing business, and the industry will have to find new ways to produce drugs if it wants to compete with companies like Pfizer, Valeant and other big pharmaceutical companies.
And those changes will take time to come.
In 2018, the British government made some significant changes to the way pharmaceutical manufacturing works.
It changed the way companies can get pharmaceutical patents, including those for their own medicines, making it easier for manufacturers to manufacture their own drugs.
After Brexit, there’s a lot more uncertainty about how the UK will enter the pharmaceutical manufacturing industry, said Mark Bostrom, director of the London School of Economics.
“There is a lot to work out about the way that we’re going and the impact that will have on the sector,” he said.